1. Home
  2. INTS vs NTIP Comparison

INTS vs NTIP Comparison

Compare INTS & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • NTIP
  • Stock Information
  • Founded
  • INTS 2012
  • NTIP 1990
  • Country
  • INTS United States
  • NTIP United States
  • Employees
  • INTS N/A
  • NTIP N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • NTIP Multi-Sector Companies
  • Sector
  • INTS Health Care
  • NTIP Miscellaneous
  • Exchange
  • INTS Nasdaq
  • NTIP Nasdaq
  • Market Cap
  • INTS 33.4M
  • NTIP 32.9M
  • IPO Year
  • INTS 2023
  • NTIP 1998
  • Fundamental
  • Price
  • INTS $2.17
  • NTIP $1.39
  • Analyst Decision
  • INTS Strong Buy
  • NTIP
  • Analyst Count
  • INTS 3
  • NTIP 0
  • Target Price
  • INTS $8.50
  • NTIP N/A
  • AVG Volume (30 Days)
  • INTS 32.4K
  • NTIP 10.6K
  • Earning Date
  • INTS 03-13-2025
  • NTIP 03-07-2025
  • Dividend Yield
  • INTS N/A
  • NTIP 7.25%
  • EPS Growth
  • INTS N/A
  • NTIP N/A
  • EPS
  • INTS N/A
  • NTIP N/A
  • Revenue
  • INTS N/A
  • NTIP $1,881,000.00
  • Revenue This Year
  • INTS N/A
  • NTIP N/A
  • Revenue Next Year
  • INTS N/A
  • NTIP N/A
  • P/E Ratio
  • INTS N/A
  • NTIP N/A
  • Revenue Growth
  • INTS N/A
  • NTIP 129.39
  • 52 Week Low
  • INTS $1.50
  • NTIP $1.22
  • 52 Week High
  • INTS $5.94
  • NTIP $2.25
  • Technical
  • Relative Strength Index (RSI)
  • INTS 44.33
  • NTIP 55.02
  • Support Level
  • INTS $1.84
  • NTIP $1.35
  • Resistance Level
  • INTS $2.53
  • NTIP $1.41
  • Average True Range (ATR)
  • INTS 0.32
  • NTIP 0.02
  • MACD
  • INTS -0.02
  • NTIP 0.00
  • Stochastic Oscillator
  • INTS 45.83
  • NTIP 80.00

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About NTIP Network-1 Technologies Inc.

Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.

Share on Social Networks: